Skip to main
OMER

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros Corp is poised for a positive financial outlook driven by its innovative therapeutic offerings, particularly the anticipated NTAP approval for YARTEMLEA, which could materially enhance revenue potential. The favorable safety profile and significant mortality reductions demonstrated in peer-reviewed studies underscore the drug's competitive advantage in treating high-risk patients, thereby justifying potential pricing at levels between $400K to $500K. Furthermore, a robust pipeline of clinical programs and upcoming catalysts presents a strategic opportunity for the company to realize value through increased market recognition and potential share re-rating based on forthcoming positive data.

Bears say

Omeros Corp faces significant challenges as it engages in the development of its clinical-stage programs, which are aimed at treating complement-mediated diseases and related conditions. The under-recognition of complications like TA-TMA in allogeneic stem cell transplantation may hinder the company's ability to effectively market its therapies and reach a broad patient population, impacting anticipated revenues. As a result, investor confidence may wane amid concerns regarding the adoption rates of its therapeutic offerings and overall market penetration.

Omeros (OMER) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Omeros (OMER) has a Strong Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $40.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $40.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.